News

In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a

It is anticipated that the acquisition will strengthen the company’s foothold in the Proteomics market and provide its customers added flexibility to leverage this exciting technology to model

Study results revealed tens of thousands of patients being treated with opioid therapy as testing positive for non-prescribed, powerful opioids like oymorphone, non-prescribed benzodiazepines like Xanax and illicit

Approved by the FDA on Aug. 27, 2015, Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that reduces

Xtampza ER, Collegium’s lead product candidate, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. The FDA will consider the advisory committees’ recommendation as

Intramuscular vaccinations of VB10.16 will be offered to patients at three different time points. Vaccibody will assess two different dosing schedules in the first phase of the study

The company treated 736 patients with type-2 diabetes inadequately controlled over a 30-week period. Full results of the trial will be communicated in a future scientific forum. The

Under the partnership, the companies will jointly select two preclinical drug candidates, one in inflammation and the other in oncology. Two preclinical drug candidates will be targeted, one

Known as the Program in Innovative Therapeutics for Connecticut’s Health or PITCH, the initiative aims to translate basic science discoveries into therapeutic strategies that can be used to